Loading clinical trials...
Loading clinical trials...
Obinutuzumab, Ibrutinib, and Venetoclax for Relapsed and Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Conditions
Interventions
Bcl-2 Inhibitor GDC-0199
Obinutuzumab
+4 more
Locations
1
United States
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Start Date
August 3, 2015
Primary Completion Date
December 24, 2021
Completion Date
April 15, 2026
Last Updated
January 27, 2026
NCT06846671
NCT07218341
NCT07030400
NCT05006716
NCT07277231
NCT06859424
Lead Sponsor
Kerry Rogers
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions